Display options
Cite
Cardenas FI, Mauguen A, Cheung IY, et al. Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers (Basel). 2021;13(24)doi: 10.3390/cancers13246265.
Cardenas, F. I., Mauguen, A., Cheung, I. Y., Kramer, K., Kushner, B. H., Ragupathi, G., Cheung, N. V., & Modak, S. (2021). Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers, 13(24), . https://doi.org/10.3390/cancers13246265
Cardenas, Fiorella Iglesias, et al. "Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma." Cancers vol. 13,24 (2021). doi: https://doi.org/10.3390/cancers13246265
Cardenas FI, Mauguen A, Cheung IY, Kramer K, Kushner BH, Ragupathi G, Cheung NV, Modak S. Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers (Basel). 2021 Dec 14;13(24). doi: 10.3390/cancers13246265. PMID: 34944886; PMCID: PMC8699451.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Dec 14;13(24). doi: 10.3390/cancers13246265.

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma.

Cancers

Fiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, Kim Kramer, Brian H Kushner, Govind Ragupathi, Nai-Kong V Cheung, Shakeel Modak

Affiliations

  1. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  2. Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

PMID: 34944886 PMCID: PMC8699451 DOI: 10.3390/cancers13246265

Abstract

Beta glucans, complex polysaccharides, prime leukocyte dectin-1 and CR3-receptors and enhance anti-tumor cytotoxicity of complement-activating monoclonal antibodies. We conducted a phase I study (clinicaltrials.gov NCT00492167) to determine the safety of the combination of yeast-derived beta glucan (BG) and anti-GD2 murine monoclonal antibody 3F8 in patients with relapsed or refractory high-risk neuroblastoma. Patients received intravenous 3F8 (fixed dose of 10 mg/m

Keywords: anti-GD2 antibody; neuroblastoma; β-glucan

References

  1. Lancet Oncol. 2018 Dec;19(12):1617-1629 - PubMed
  2. JAMA Oncol. 2018 Dec 1;4(12):1729-1735 - PubMed
  3. Vaccine. 2008 Sep 2;26(37):4860-5 - PubMed
  4. J Clin Oncol. 2012 Sep 10;30(26):3264-70 - PubMed
  5. Biosci Rep. 2019 Nov 29;39(11): - PubMed
  6. Cancer Immunol Immunother. 2002 Nov;51(10):557-64 - PubMed
  7. Blood. 1992 Mar 15;79(6):1484-90 - PubMed
  8. Nat Rev Immunol. 2006 Jan;6(1):33-43 - PubMed
  9. J Clin Oncol. 2021 Jan 20;39(3):215-226 - PubMed
  10. N Engl J Med. 2010 Sep 30;363(14):1324-34 - PubMed
  11. Leuk Res. 2005 Jun;29(6):679-83 - PubMed
  12. Med Pediatr Oncol. 2000 Dec;35(6):635-7 - PubMed
  13. Oncoimmunology. 2015 May 22;4(7):e1016704 - PubMed
  14. Pediatr Blood Cancer. 2021 Oct;68(10):e29121 - PubMed
  15. Immunobiology. 2021 Mar;226(2):152071 - PubMed
  16. Br J Cancer. 2016 Oct 25;115(9):1048-1057 - PubMed
  17. Clin Cancer Res. 2014 Mar 1;20(5):1375-82 - PubMed
  18. Drugs Future. 2010;35(8):665 - PubMed
  19. Pediatr Clin North Am. 2015 Feb;62(1):225-56 - PubMed
  20. Front Immunol. 2018 Feb 26;9:341 - PubMed
  21. Cancer Res. 2003 Dec 15;63(24):9023-31 - PubMed
  22. Cancer Res. 1994 Apr 15;54(8):2228-33 - PubMed
  23. Cancer Res. 2005 Nov 15;65(22):10562-8 - PubMed
  24. Cancer Med. 2019 Dec;8(17):7236-7243 - PubMed
  25. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189 - PubMed
  26. Blood. 2011 Jun 23;117(25):6825-36 - PubMed
  27. Oncoimmunology. 2013 Mar 1;2(3):e23402 - PubMed
  28. Front Immunol. 2020 Apr 22;11:658 - PubMed
  29. J Clin Oncol. 1993 Aug;11(8):1466-77 - PubMed
  30. Cancer. 2017 Dec 15;123(24):4914-4923 - PubMed

Publication Types